Salah Aref, Mohamed El Agdar, Nada Khaled, Lamyaa Ibrahim, Mohamed S El-Ghonemy
{"title":"成人b细胞急性淋巴细胞白血病患者CD25/CD123共表达的临床影响","authors":"Salah Aref, Mohamed El Agdar, Nada Khaled, Lamyaa Ibrahim, Mohamed S El-Ghonemy","doi":"10.1155/2020/9545717","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to determine the clinical impact of CD25<sup>+</sup>/CD123<sup>+</sup> coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assessed using flow cytometry. CD25<sup>+</sup>/CD123<sup>+</sup> coexpression was detected in 40/120 B-ALL patients (33.3%). All B-ALL patients showed CD25<sup>+</sup>/CD123<sup>+</sup> coexpression had lower induction of remission response and shorter overall survival as compared to B-ALL cases lacking coexpression. In conclusion, CD25<sup>+</sup>/CD123<sup>+</sup> positive coexpression is a reliable flow cytometry marker for prediction of the outcome of adult B-ALL patients and could be used as a novel parameter for risk stratification of adult B-ALL cases.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2020 ","pages":"9545717"},"PeriodicalIF":0.0000,"publicationDate":"2020-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9545717","citationCount":"0","resultStr":"{\"title\":\"Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients.\",\"authors\":\"Salah Aref, Mohamed El Agdar, Nada Khaled, Lamyaa Ibrahim, Mohamed S El-Ghonemy\",\"doi\":\"10.1155/2020/9545717\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study aimed to determine the clinical impact of CD25<sup>+</sup>/CD123<sup>+</sup> coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assessed using flow cytometry. CD25<sup>+</sup>/CD123<sup>+</sup> coexpression was detected in 40/120 B-ALL patients (33.3%). All B-ALL patients showed CD25<sup>+</sup>/CD123<sup>+</sup> coexpression had lower induction of remission response and shorter overall survival as compared to B-ALL cases lacking coexpression. In conclusion, CD25<sup>+</sup>/CD123<sup>+</sup> positive coexpression is a reliable flow cytometry marker for prediction of the outcome of adult B-ALL patients and could be used as a novel parameter for risk stratification of adult B-ALL cases.</p>\",\"PeriodicalId\":7325,\"journal\":{\"name\":\"Advances in Hematology\",\"volume\":\"2020 \",\"pages\":\"9545717\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/9545717\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/9545717\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/9545717","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients.
This study aimed to determine the clinical impact of CD25+/CD123+ coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assessed using flow cytometry. CD25+/CD123+ coexpression was detected in 40/120 B-ALL patients (33.3%). All B-ALL patients showed CD25+/CD123+ coexpression had lower induction of remission response and shorter overall survival as compared to B-ALL cases lacking coexpression. In conclusion, CD25+/CD123+ positive coexpression is a reliable flow cytometry marker for prediction of the outcome of adult B-ALL patients and could be used as a novel parameter for risk stratification of adult B-ALL cases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
